ArticleJournal of medicinal chemistry2026

Targeting Activin Receptor-like Kinase 2 Using Heterobifunctional Protein Degraders.

Daniel T Webb et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.